Repligen/$RGEN

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Repligen

Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 58% of 2024 revenue, while chromatography, proteins, and process analytics were 19%, 12%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.

Ticker

$RGEN
Sector
Primary listing

Employees

1,778

Repligen Metrics

BasicAdvanced
$8.4B
-
-$0.25
1.08
-

What the Analysts think about Repligen

Analyst ratings (Buy, Hold, Sell) for Repligen stock.

Bulls say / Bears say

Repligen reported Q2 2025 revenue of $182 million, a 15% year-over-year increase, with 17% organic growth ex-COVID across all business lines, highlighting a strong recovery in demand (Nasdaq).
Q2 orders grew over 20% sequentially, marking the eighth straight quarter where orders beat non-COVID revenue and supporting strong visibility for future backlog (Nasdaq).
In Q1 2025, Repligen acquired 908 Devices’ bioprocessing business and launched the CTech™ SoloVPE® Plus System, further strengthening its process analytics division and growth prospects (Nasdaq)
GAAP gross margin in Q2 2025 fell to 50.0%, down from 51.3% a year ago, pointing to rising cost pressures and a risk of margin erosion in the future (Globe Newswire).
Management stated new modalities would create a 1% drag on full-year revenue, revealing execution risk and limited visibility in newer market segments (Globe Newswire).
Full-year guidance factors in small tariff surcharges, suggesting exposure to changes in trade policy and risk of input cost increases (Globe Newswire).
Data summarised monthly by Lightyear AI. Last updated on 3 Oct 2025.

Repligen Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Repligen Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $RGEN

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs